US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% META $728.08 ▲+0.00% TSLA $370.59 ▲+0.00% JNJ $256.03 ▲+0.00% AMD $633.91 ▲+0.00% NVDA $233.95 ▲+0.00% SPCX $158.96 ▲+0.00%
FinancialContent

Articles published by Dicerna Pharmaceuticals, Inc.

News headline image
Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition
From Dicerna Pharmaceuticals, Inc.
Via Business Wire
News headline image
Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna
From Dicerna Pharmaceuticals, Inc.
Via Business Wire
News headline image
Novo Nordisk to Acquire Dicerna
From Dicerna Pharmaceuticals, Inc.
Via Business Wire
News headline image
Dicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With Lilly
From Dicerna Pharmaceuticals, Inc.
Via Business Wire
News headline image
Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021
From Dicerna Pharmaceuticals, Inc.
Via Business Wire
News headline image
Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update
From Dicerna Pharmaceuticals, Inc.
Via Business Wire
News headline image
Dicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021
From Dicerna Pharmaceuticals, Inc.
Via Business Wire
News headline image
Dicerna to Report Third Quarter 2021 Financial Results on Nov. 9, 2021
From Dicerna Pharmaceuticals, Inc.
Via Business Wire
News headline image
Dicerna Announces Results for PHYOX™4, Single-Dose Study of Nedosiran in Primary Hyperoxaluria Type 3 (PH3)
From Dicerna Pharmaceuticals, Inc.
Via Business Wire
News headline image
Dicerna Announces Data to Be Presented at American Society of Nephrology (ASN) Kidney Week 2021
From Dicerna Pharmaceuticals, Inc.
Via Business Wire
News headline image
Dicerna Announces Poster Presentations at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021 in November
From Dicerna Pharmaceuticals, Inc.
Via Business Wire
News headline image
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Dicerna Pharmaceuticals, Inc.
Via Business Wire
News headline image
Dicerna Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC™ RNAi Therapeutic Candidate for the Treatment of Alcohol Use Disorder
From Dicerna Pharmaceuticals, Inc.
Via Business Wire
News headline image
Dicerna Announces New Executive Leadership Appointments
From Dicerna Pharmaceuticals, Inc.
Via Business Wire
News headline image
Dicerna to Participate in 16th Annual Citi Biopharma Conference
From Dicerna Pharmaceuticals, Inc.
Via Business Wire
News headline image
Dicerna Announces Second Quarter 2021 Financial Results and Provides a Business Update
From Dicerna Pharmaceuticals, Inc.
Via Business Wire
News headline image
Dicerna Reports Positive Top-Line Results From PHYOX™2 Pivotal Clinical Trial of Nedosiran for the Treatment of Primary Hyperoxaluria
From Dicerna Pharmaceuticals, Inc.
Via Business Wire
News headline image
Dicerna to Report Second Quarter 2021 Financial Results on Aug. 9, 2021
From Dicerna Pharmaceuticals, Inc.
Via Business Wire
News headline image
Dicerna Announces FDA Clearance of Investigational New Drug (IND) Application for DCR-AUD for the Treatment of Alcohol Use Disorder
From Dicerna Pharmaceuticals, Inc.
Via Business Wire
News headline image
Dicerna Announces Interim Results From Phase 1 Trial of Belcesiran for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
From Dicerna Pharmaceuticals, Inc.
Via Business Wire
News headline image
Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Dicerna Pharmaceuticals, Inc.
Via Business Wire
News headline image
Dicerna Initiates Patient Dosing in ESTRELLA Phase 2 Clinical Trial of Belcesiran for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
From Dicerna Pharmaceuticals, Inc.
Via Business Wire
News headline image
Dicerna Announces Dosing Completion in Nedosiran PHYOX™4 Clinical Trial for Treatment of Primary Hyperoxaluria Type 3
From Dicerna Pharmaceuticals, Inc.
Via Business Wire
News headline image
Dicerna to Participate in 42nd Annual Goldman Sachs Global Healthcare Conference
From Dicerna Pharmaceuticals, Inc.
Via Business Wire
News headline image
Dicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for LY3819469
From Dicerna Pharmaceuticals, Inc.
Via Business Wire
News headline image
Dicerna Announces Boehringer Ingelheim’s Acceptance of Candidate for Development Under RNAi Research Collaboration and License Agreement
From Dicerna Pharmaceuticals, Inc.
Via Business Wire
News headline image
Dicerna to Participate in Upcoming Investor Conferences
From Dicerna Pharmaceuticals, Inc.
Via Business Wire
News headline image
Dicerna Announces First Quarter 2021 Financial Results and Provides a Business Update
From Dicerna Pharmaceuticals, Inc.
Via Business Wire
News headline image
Dicerna to Report First Quarter 2021 Financial Results on May 6, 2021
From Dicerna Pharmaceuticals, Inc.
Via Business Wire
News headline image
Dicerna Sells OXLUMO™ (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million
From Dicerna Pharmaceuticals, Inc.
Via Business Wire
Tickers RPRX